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Abstract
Porphyromonas gingivalis is the primary etiologic agent of periodontal disease that is associated with other human chronic
inflammatory diseases, including atherosclerosis. The ability of P. gingivalis to invade and persist within human aortic
endothelial cells (HAEC) has been postulated to contribute to a low to moderate chronic state of inflammation, although
how this is specifically achieved has not been well defined. In this study, we demonstrate that P. gingivalis infection of HAEC
resulted in the rapid cleavage of receptor interacting protein 1 (RIPK1), a mediator of tumor necrosis factor (TNF) receptor-1
(TNF-R1)-induced cell activation or death, and RIPK2, a key mediator of both innate immune signaling and adaptive
immunity. The cleavage of RIPK1 or RIPK2 was not observed in cells treated with apoptotic stimuli, or cells stimulated with
agonists to TNF-R1, nucleotide oligomerization domain receptor 1(NOD1), NOD2, Toll-like receptor 2 (TLR2) or TLR4. P.
gingivalis-induced cleavage of RIPK1 and RIPK2 was inhibited in the presence of a lysine-specific gingipain (Kgp) inhibitor.
RIPK1 and RIPK2 cleavage was not observed in HAEC treated with an isogenic mutant deficient in the lysine-specific
gingipain, confirming a role for Kgp in the cleavage of RIPK1 and RIPK2. Similar proteolysis of poly (ADP-ribose) polymerase
(PARP) was observed. We also demonstrated direct proteolysis of RIPK2 by P. gingivalis in a cell-free system which was
abrogated in the presence of a Kgp-specific protease inhibitor. Our studies thus reveal an important role for pathogen-
mediated modification of cellular kinases as a potential strategy for bacterial persistence within target host cells, which is
associated with low-grade chronic inflammation, a hallmark of pathogen-mediated chronic inflammatory disorders.
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Introduction
RIPK1 and RIPK2 belong to a novel class of kinases that
function in cell survival and cell death mechanisms [1,2,3]. The
serine/threonine kinases share a conserved kinase domain and
have distinct protein-protein interaction motifs, including a death
domain in RIPK1 or a caspase activation and recruitment domain
(CARD) in RIPK2. RIPK1 and RIPK2 participate in distinct
cellular responses. RIPK1 is primarily involved in mediating TNF-
R1-induced cell activation, apoptosis and necroptosis [4]. In
contrast, RIPK2 functions as a key signaling protein in host
defense responses induced by activation of the cytosolic pattern
recognition receptors (PRR) NOD1 and NOD2 which sense the
evolutionarily conserved bacterial peptidoglycan motifs, including
meso-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP)
[5,6,7,8,9,10,11,12]. RIPK2 has also been reported to mediate
other cellular responses, including TLR signaling [13,14,15,16],
caspase 1 activation [17], apoptosis [1] and autophagy [18].
Increasing evidence demonstrates that both TNF-R1 and
NOD-like receptor (NLR) pathways are regulated by and activate
similar downstream signaling proteins [3,16,19,20,21]. However,
the mechanisms that distinguish if RIPK1 and RIPK2 promote
either cell survival or cell death signaling pathways are not fully
understood. Induction of apoptosis through activation of death
receptors (TNF-R1, Fas, DR3, DR4 or DR5) promotes the
caspase-mediated cleavage of RIPK1 resulting in the generation of
biologically active fragments with distinct functions that modulate
NF-kB-mediated cell survival or death [22,23]. A similar caspase-
mediated cleavage of active fragments is observed with the cognate
pronecrotic kinase RIPK3 and RIPK4 [24,25]. The ability of
particular protein motifs of RIPK1 to modify cell fate may be
governed by post-translational modifications [19,26] and the
ability of death receptors to distinguish between various adaptor
proteins [27].
Periodontitis is a destructive chronic inflammatory disease of the
oral cavity that is mediated by a robust immune response to
infection with pathogenic bacteria. Among the community of
microorganisms associated with periodontitis, the Gram-negative
anaerobe, P. gingivalis is a key etiologic agent of the disease. In
addition to chronic inflammation at the initial site of infection,
mounting evidence has accumulated supporting a role for P.
gingivalis-mediated periodontal disease as a risk factor for systemic
diseases including diabetes, pre-term birth, and cardiovascular
disease [28,29]. Dissemination of P. gingivalis from the oral cavity
in humans is documented and P. gingivalis has been detected in
human atheromas [30].
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the role of P. gingivalis in the contribution of atherosclerosis. Our
laboratory and others have demonstrated that oral challenge of
ApoE
2/2 mice with P. gingivalis induces alveolar bone loss and
increases the mean area and extent of atherosclerotic lesion
development in the aortic arch in mice maintained on a normal
chow diet [31,32]. Aortic tissue analysis from P. gingivalis-
challenged ApoE
2/2 mice demonstrate increased inflammatory
markers and activation of the endothelium, including increased
numbers of monocytes and elevated levels of cell adhesion
molecules (CAM), TLR and expression of cytokines
[31,32,33,34]. Furthermore, high titers of systemic P. gingivalis-
specific antibodies are generated and detection of P. gingivalis-
specific 16S DNA by PCR in blood and aortic tissues has been
observed early after oral challenge of ApoE
2/2 mice [31,32,33].
In vitro studies have established that P. gingivalis invades and
survives within endothelial cells which is associated with the
activation of the endothelium. P. gingivalis activation of endothelial
cells is associated with up regulation of proinflammatory genes
[33], elevation in cell surface expression of CAM [33,35,36,37],
TLR [31,38], and the secretion of chemokines [33,37,39].
Following major fimbriae-mediated attachment, minor fimbriae
play a role in more intimate attachment facilitating uptake [37]. P.
gingivalis uptake into endothelial cells occurs quickly (30 min)
[36,37,40], and upon entry P. gingivalis traffics to and resides in a
late autophagosome [40]. The ability of P. gingivalis to both persist
within endothelial cells and to activate inflammatory cascades has
been postulated to play a role in low grade chronic inflammation
associated with P. gingivalis infection [37]. P. gingivalis has a number
of elaborate mechanisms which are utilized to evade detection and
eradication by the immune system, including modification of lipid
A, the biological core of bacterial LPS, and through activities
associated with bacterial cysteine proteases (referred to as
gingipains) [35,37,39]. The gingipains are transcribed from three
genes, rgpA, rgpB, and kgp, producing arginine (R)-specific (RgpA
and RgpB) or lysine-specific (Kgp) gingipains, that cleave after an
arginine or a lysine residue, respectively [41,42,43]. The
gingipains are non-covalently attached to the bacterial surface
and can be secreted in vesicle-bound molecules or as monomers
[41,44]. Importantly, gingipains cleave a number of host cell
proteins to facilitate P. gingivalis invasion [39], survival and
colonization [45,46].
In this study, we demonstrate that P. gingivalis infection of
HAEC results in the rapid cleavage of RIPK1 and RIPK2, key
mediators of cell survival, death and host defense. Our findings
reveal that proteolysis of intracellular signaling kinases by bacterial
lysine-specific proteases alters host defense responses and provides
a potential mechanism for bacterial persistence within target host
cells. Together with other recently described mechanisms for P.
gingivalis host immune evasion, our work supports the emerging
concept that pathogen-mediated chronic inflammatory disorders
result from specific pathogen-mediated evasion strategies associ-
ated with low grade chronic inflammation.
Results
Induction of RIPK1 and RIPK2 proteolysis in HAEC treated
with P. gingivalis
We previously demonstrated that P. gingivalis induces the
activation (defined as an up regulation of cell surface CAM,
TLR, activation of NF-kB and secretion of chemokines, including
IL-8 and MCP-1) of primary HAEC and human umbilical vein
endothelial cells (HUVEC) in tissue culture [33,35,37,39,47] and
acceleration of aortic lesion development in mouse models of P.
gingivalis infection via TLR mediated signaling [31,34,38]. To
begin to address the role of P. gingivalis-mediated intracellular
signaling responses in HAEC, we first examined the expression
level of the intracellular kinases RIPK1 and RIPK2. HAEC were
treated with live organism at a multiplicity of infection (MOI) of
100 and protein levels were monitored over time. Target sites of
antibodies to RIPK1 and RIPK2 used in this study are described
in Figure S1. Treatment of HAEC with P. gingivalis strain 381
induced an immediate (15 min) and significant reduction of full-
length RIPK1 and RIPK2 protein levels as determined by
Western blot analysis of whole cell lysates (Figure 1A and B).
The reduction of full-length RIPK1 and RIPK2 in HAEC was
transient since full-length protein levels were observed at later time
points. We also observed prominent low molecular weight (LMW)
immunoreactive bands in samples treated with P. gingivalis with an
antibody to RIPK1 (14-, 28- and 32-kDa) (Figure 1A and
Figure 2), and with antibodies directed to the N9-terminal and
C9-terminal region of RIPK2 (20- and 42-kDa), respectively
(Figure 1B). Noteworthy, the sum of the immunoreactive bands
observed for RIPK1 and RIPK2 was approximate to the
molecular weight of RIPK1 (74-kDa) and RIPK2 (61-kDa),
respectively. The detection of multiple bands with the RIPK2 C9-
terminal antibody (Figure 1B-right panel) may represent
fragments of additional proteolytic processing of RIPK2 following
an initial cleavage event. Similar findings were observed in
HUVEC (data not shown). In contrast to RIPK1 and RIPK2, we
did not observe LMW immunoreactive bands with antibodies to
NOD1 or NOD2, the cytosolic PRR of RIPK2, in HAEC treated
with P. gingivalis. However, NOD1 levels were decreased in
response to P. gingivalis with an initial decrease in protein levels and
a partial recovery later in the infection. NOD2 levels were
relatively stable in response to P. gingivalis as to untreated HAEC.
(Figure 1C).
The P. gingivalis-induced proteolysis of RIPK1 and RIPK2 was
dose-dependent (Figure 2). To determine if live P. gingivalis was
required for the reduction of RIPK1 and RIPK2, HAEC were
Author Summary
A number of successful pathogens have evolved mecha-
nisms to evade host defenses, thus establishing persistent
and chronic infections. Although membrane-bound innate
immune receptors including Toll-like receptors play a role
in inflammation in response to the common oral pathogen
Porphyromonas gingivalis, it is not known how intracellular
host defense mechanisms to this pathogen contribute to
persistent infection and resulting chronic inflammation. In
this study, we have defined a novel strategy by which P.
gingivalis modulates the levels of key intracellular proteins
involved in cell death and host defense responses. We
demonstrate that the lysine-specific bacterial cysteine
protease of P. gingivalis (Kgp) induces the proteolysis of
receptor interacting protein kinase 1 (RIPK1), RIPK2 and
poly (ADP-ribose) polymerase (PARP). Although endoge-
nous host mechanisms may contribute to this process,
activation of innate immune signaling cascades, caspases,
or apoptosis alone were not sufficient to drive proteolysis.
These findings support a role for pathogen-mediated
modification of cellular kinases as a strategy for bacterial
persistence within target host cells. Together with other
recently described mechanisms for P. gingivalis host
immune evasion, our work supports the emerging concept
that pathogen-mediated chronic inflammatory disorders
result from specific pathogen-mediated evasion strategies
resulting in low-grade chronic inflammation.
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80uC). Partial proteolysis of RIPK1 and RIPK2 was observed in
HAEC treated with P. gingivalis cultures performed at 60uC, but not
at 80uC suggesting that the ability of P. gingivalis to degrade RIPK1
and RIPK2 was dependent on a heat-labile bacterial protein
(Figure 2).
The P. gingivalis major fimbriae mediate attachment to cells by
interacting with host cell surface integrins and membrane-bound
PRR [48]. Interfering with this interaction inhibits the ability of P.
gingivalis to invadehost cells within tissue culture systems [35,47]. To
determine if the major fimbriae was required for the modification of
RIPK1 and RIPK2 in endothelial cells, protein levels in HUVEC
were compared in cells treated with either the P. gingivalis major
fimbriae-deficient strain DPG3 to wild type strain 381. As expected
P. gingivalis strain 381 induced a dose-dependent reduction of
RIPK1 and RIPK2 levels and induction of LMW immunoreactive
bands (Figure S2). Importantly, full-length RIPK1 and RIPK2
levels were not significantly reduced in endothelial cells treated with
P. gingivalis strain DPG3. These observations suggest that the
functional activity of P. gingivalis fimbriae contribute to the observed
proteolysis of RIPK1 and RIPK2.
To determine if the LMW immunoreactive bands observed
following incubation with P. gingivalis were products of new protein
synthesis or a putative cleaved fragments of RIPK1 or RIPK2,
HUVEC were pretreated with the protein synthesis inhibitor
cycloheximide (CHX) prior to stimulation with P. gingivalis.
Pretreatment with CHX did not alter the ability of P. gingivalis to
induce the proteolysis of RIPK1 or RIPK2 (Figure S3). These
findings indicate that the LMW immunoreactive bands observed
in P. gingivalis treated cells, were not products of new protein
synthesis and suggest that they are cleavage fragments of RIPK1
or RIPK2, respectively. Collectively, these results demonstrate that
P. gingivalis induced the immediate, transient, dose-dependent
proteolysis of RIPK1 and RIPK2 through a fimbriae-facilitated
and heat-labile process.
RIPK2 levels are stable in HAEC following stimulation with
TLR or NLR agonists or following stimulation with TNFa
To determine if P. gingivalis-induced proteolysis of RIPK2 was a
result of cell activation via TLR or NLR-mediated signaling,
HAEC were treated with a panel of synthetic or purified agonists
to PRR that have been demonstrated to be activated by P. gingivalis
or are direct activators of the NOD/RIPK2 signaling pathway.
HAEC were untreated or treated with live P. gingivalis or with
agonists to PRR, including Pam3CSK4, FSL-1, P. gingivalis LPS, E.
coli LPS, iE-DAP, MDP or TNFa as a non-PRR activator of NF-
kB or their vehicle controls for 2, 6, 12 and 24 h. To facilitate the
passage of iE-DAP or MDP through the cell membrane, acylated
derivatives of iE-DAP (C12-iE-DAP) and MDP (L18-MDP) were
also used. Stimulation of HAEC with the panel of agonists did not
result in the proteolysis of full-length RIPK2 or its mRNA splice
variant, RIPK2b [49] (Figure 3). Similar results were obtained
using a 100-fold range for all agonists examined over the full time
course of the experiment (data not shown). Treatment of HAEC
with the agonists resulted in the induction of IL-8 levels in a
manner dependent on the agonist and concentration used (Figure
S4). Noteworthy, NOD1 agonists (iE-DAP and C12-iE-DAP)
induced significantly higher IL-8 levels in comparison to NOD2
Figure 1. P. gingivalis 381-induced proteolysis of RIPK1 and RIPK2 in HAEC. HAEC were treated with medium (M) or with P. gingivalis strain
381 (MO1 100) for 0.25, 0.5, 1, 2, 6, 12, 24 or 48 h. Whole cell lysates were analyzed for the detection of A) RIPK1, B) RIPK2 with an anti N9-terminal
RIPK2 antibody (left panel) or an anti C9-terminal RIPK2 antibody (right panel), or C) NOD1 (left panel) and NOD2 (right panel). Full-length RIPK1 (74-
kDa) and RIPK2 (61-kDa) are indicated with arrows. Prominent P. gingivalis-induced LMW bands are indicated with asterisks. Molecular weight (MW)
ladder is indicated on the left in kDa. GAPDH was detected as a loading control. (2) protein levels in medium-treated cells were similar at all time
points. Densitometric analysis is presented below respective blots as the mean (+/2 SEM) ratio of NOD1 (or NOD2) to GAPDH protein levels (arbitrary
densitometric units (A.D.U.) from at least 3 independent membranes. Means are displayed within the bar charts.
doi:10.1371/journal.ppat.1002723.g001
Figure 2. P. gingivalis-induced proteolysis of RIPK proteins is dose-dependent and heat labile. HAEC were treated with medium (M), live
P. gingivalis strain 381 (MOI 10) (10), live P. gingivalis (MOI 100) (100), heat-killed (HK) (60uC, 60 min) P. gingivalis 381 (MOI 100 equivalency) (606), or
with HK (80uC, 20 min) P. gingivalis 381 (MOI 100 equivalency) (806) for 2 h. Whole cell lysates were analyzed for the detection of RIPK1 (left panel) or
RIPK2 (right panel). Full-length RIPK1 and RIPK2 are indicated with arrows. Prominent P. gingivalis-induced LMW bands are indicated with asterisk(s).
MW ladder is indicated on the left in kDa. GAPDH was detected as a loading control.
doi:10.1371/journal.ppat.1002723.g002
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tively, these findings suggest that the modification of RIPK2
observed in HAEC treated with P. gingivalis was not simply due to
the activation of a single TLR, NOD or TNF-R1 canonical
signaling pathway but a response driven by P. gingivalis.
The proteolysis of RIPK1 and RIPK2 does not a result from
the induction of apoptosis
To determine if P. gingivalis-induced proteolysis of RIPK1 and
RIPK2 was a product of apoptosis, we treated cells with apoptotic
stimuli and monitored apoptosis by flow cytomery detection of
annexin V/propidium iodide staining and by Western blot
detection of cleaved caspase 3 and its substrate PARP. Treatment
of HUVEC with staurosproine or co-treatment with CHX and
TNFa (CHX+TNFa) induced significant apoptotic cell popula-
tions as compared to HUVEC treated with CHX alone, TNFa
alone or medium (Figure S5A). We also observed dose-dependent
apoptotic cell populations treated with P. gingivalis 381, suggesting
that a proportion of the cells undergo apoptosis in response to
infection. Induction of apoptosis of HUVEC by staurosporine or
CHX+TNFa treatment was also confirmed through the cleavage
of caspase 3 and PARP (Figure S5B). Importantly, we did not
observe the induction of RIPK1 or RIPK2 cleavage in HUVEC in
response to staurosporine or CHX+TNFa treatment (Figure 4).
Furthermore, P. gingivalis itself did not induce the cleavage of
caspase 3, but appeared to induce the complete proteolysis of
PARP. These findings demonstrate that apoptotic stimuli alone do
not induce the cleavage of RIPK1 or RIPK2 in HUVEC.
Role of caspases in P. gingivalis-induced proteolysis of
RIPK1 and RIPK2
Previous reports have identified a caspase-mediated cleavage of
RIPK1, RIPK3 and RIPK4 during death receptor-mediated
apoptosis [22,23,24,25]. Despite these reports, prior to our study
there have been no reports demonstrating the cleavage of RIPK2
under any condition. To determine if caspase inhibitors prevented
the proteolysis of RIPK1 and RIPK2 in cells treated with P.
gingivalis, HUVEC were pretreated with the general caspase
inhibitors zVAD-FMK, Boc-D-FMK or vehicle control prior to
addition of live organism to the cell culture. We confirmed that the
general caspase inhibitors abrogated caspase activity as monitored
by inhibition of staurosporine-induced PARP cleavage (Figure S6-
lower panel). Treatment of cells with general caspase inhibitors
interfered with P. gingivalis-mediated proteolysis of RIPK1
(Figure 5A, Figure S6-top panel) and RIPK2 (Figure 5B
and Figure S6-mid panel). While these findings suggest that
caspases are involved in the proteolysis of RIPK2, FMK-linked
general and enzyme-specific caspase inhibitors have been demon-
strated to inhibit the proteolytic activity of the P. gingivalis cysteine
protease Kgp, but not the arginine-specific gingipains [50].
Importantly, both caspases and gingipains are classified under
the same clan of cysteine proteases (C25), as they share similar
active sites, structural motifs and are subject to similar modes of
chemical inhibition [51]. Thus, the ability of caspase inhibitors to
interfere with P. gingivalis-induced RIPK2 proteolysis by caspases
inhibitors may reflect an inhibition of host caspase activity, P.
gingivalis Kgp activity, or both.
To examine the role of cellular caspase activity in P. gingivalis-
induced proteolysis of RIPK2 directly, murine bone marrow
derived macrophages (BMDM) from casp1-, casp2-, casp3-, or
casp7-deficient mice were co-cultured with P. gingivalis. P. gingivalis
induced a similar proteolysis of RIPK2 in cells deficient in casp1
(Figure 6A), casp2, casp3,o rcasp7 (Figure 6B) as that observed
in wild type cells. These findings suggest that caspase 1, caspase
2, caspase 3 and caspase 7 singly do not play a role in P.
gingivalis-induced RIPK2 proteolysis. However, they do not
exclude the possibility that non-redundant host caspase activity
could contribute to RIPK2 cleavage induced by P. gingivalis
stimulation.
Figure 3. RIPK2 levels are stable in HAEC stimulated with TLR or NLR agonists. HAEC were treated with medium, P. gingivalis 381 (MOI
100), 10 mg/ml Pam3CSK4, 10 mg/ml FSL-1, 10 mg/ml P. gingivalis 381 LPS, 1.0 mg/ml E. coli 0111:B4 LPS, 100 ng/ml recombinant human TNF, 100 mg/
ml iE-DAP, 100 mg/ml iE-DAP control, 1000 ng/ml C12-iE-DAP, 0.01% DMSO (C12-iE-DAP vehicle control), 100 mg/ml MDP, 100 mg/ml MDP control, or
1000 ng/ml L18-MDP for 2 h. Whole cell lysates were analyzed for the detection of RIPK2 and GAPDH. Full-length RIPK2 and RIPK2b are indicated with
arrows. A prominent P. gingivalis-induced LMW band is indicated with an asterisk. MW ladder is indicated on the left in kDa.
doi:10.1371/journal.ppat.1002723.g003
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is abrogated with peptide inhibition of Kgp
A number of host cell surface proteins and proteins in the
extracellular milieu are cleaved by the cysteine proteases of P.
gingivalis [44,52,53]. To evaluate if P. gingivalis gingipains played a
role in the proteolysis of RIPK1 and RIPK2, we first evaluated
previously established gingipain-specific inhibitors KYT-1 (argi-
nine-specific gingipain inhibitor) and KYT-36 (lysine-specific
gingipain inhibitor) [54,55] as well as TLCK, which inhibits both
arginine-specific and lysine-specific protease activity [56] in our
studies. We confirmed the ability of the protease inhibitors to
reduce the arginine-specific activity by KYT-1, the lysine-specific
activity by KYT-36 and both arginine- and lysine-specific protease
activity by TLCK in a substrate-based assay (Figure 7A and B).
Treatment of P. gingivalis 381 with KYT-1 or vehicle control
(DMSO) did not alter the ability of P. gingivalis 381 to induce
proteolysis of RIPK1 (Figure 8A) or RIPK2 (Figure 8B)i n
HAEC. However, treatment of P. gingivalis with KYT-36 alone or
in combination with KYT-1 blocked P. gingivalis-induced proteol-
ysis of RIPK1 and RIPK2. TLCK also inhibited the P. gingivalis-
induced proteolysis of RIPK1 and RIPK2. Pretreatment of P.
gingivalis with KYT-1, KYT-36, TLCK and vehicle controls did
not alter bacterial viability (data not shown), nor did KYT-36 alter
host caspase 3 activity (Figure 7C). These findings indicate that
Kgp activity was responsible for P. gingivalis-mediated proteolysis of
RIPK1 and RIPK2.
RIPK1 and RIPK2 levels in HAEC are unaltered with the P.
gingivalis kgp-deficient mutant strain YPP2
To further confirm the role of P. gingivalis gingipains in the
proteolysis of RIPK1 and RIPK2 in the absence of chemical
inhibitors, we examined previously characterized bacterial
mutant strains deficient in kgp or rgp [57] for their ability to
induce the proteolysis of RIPK1 and RIPK2. The genetic
background of the mutant strains used was in P. gingivalis strain
33277, a similarly classified organism in terms of clonality (clonal
type 1) [58] serogroup (A) [59] and invasiveness [60] as P.
gingivalis strain 381. We observed that P. gingivalis wild type strain
33277 reduced full-length RIPK1 (Figure 9A) and RIPK2
(Figure 9B) levels and induced the detection of LMW
immunoreactive bands. However, the degree of RIPK1 and
RIPK2 proteolysis induced by 33277 was less than that observed
with strain 381. Both P. gingivalis strains YPP1 and RgpA/B
induced a significant proteolysis of full-length RIPK1 and
RIPK2. In contrast, RIPK1 and RIPK2 protein levels in HAEC
treated with P. gingivalis YPP2 were similar to untreated cells.
These findings confirm the role of Kgp in P. gingivalis-induced
proteolysis of RIPK1 and RIPK2.
P. gingivalis Kgp activity induces the proteolysis of PARP
Initially monitoring the cleavage of the nuclear DNA repair
enzyme PARP [61,62,63] as a marker of caspase-mediated
apoptosis, we serendipitously observed that P. gingivalis induced
the proteolysis of PARP in the absence and presence of broad-
based caspase inhibition (Figure S6). The kinetics of PARP levels
in response to P. gingivalis followed an immediate proteolysis
(15 min) that was sustained until 24 h of co-culture when PARP
levels began to return to baseline (Figure S7A). We noted the
proteolysis of PARP was dose-dependent and that the absence of
PARP detection was noted in both soluble and insoluble cellular
fractions (data not shown). We thus further evaluated the role of
gingipain activity on the proteolysis of PARP through chemical
inhibition or through the use of isogenic mutants lacking
gingipains as described above for RIPK1 and RIPK2. We
observed a similar pattern of P. gingivalis-induced proteolysis of
PARP as to that observed with RIPK1 and RIPK2 when using
specific gingipain inhibitors or bacterial mutants (Figure S7B
and C). These findings suggest that not only are RIPK1 and
RIPK2 proteins subject to Kgp-induced proteolysis, but other key
regulatory proteins involved in regulating apoptosis (such as
PARP) may be subject to similar proteolysis in response to P.
gingivalis.
P. gingivalis induces the cleavage of recombinant RIPK2
kinase domain independent of host cell proteins
To determine if P. gingivalis was capable of cleaving RIPK2 in
the absence of host cell proteins, recombinant RIPK2 kinase
domain (rRIPK2 kd) was incubated with P. gingivalis and analyzed
Figure 4. Classical apoptotic stimuli do not induce the proteolysis of RIPK1 or RIPK2 in HUVEC. HUVEC were treated with medium, P.
gingivalis 381 (MOI 100), 2 mM staurosporine (STS)2 5mg/ml cycloheximide (CHX), 10 ng/ml TNFa, or co-treated with 25 mg/ml CHX and 10 ng/ml
TNFa for 6 h. Whole cell lysates were analyzed for the detection of RIPK1 (left panel) or RIPK2 (right panel). Full-length RIPK1 and RIPK2 are indicated
with arrows. Prominent P. gingivalis-induced LMW bands are indicated with asterisks. MW ladder is indicated on the left in kDa. GAPDH was detected
as a loading control.
doi:10.1371/journal.ppat.1002723.g004
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antibody targeting the N9-terminal kinase domain. As shown in
Figure 10, rRIPK2 kd migrates at ,40-kDa and was cleaved in
the presence of P. gingivalis 381. Furthermore, KYT-1 partially
inhibited P. gingivalis-induced cleavage of RIPK2 kd. Surprisingly,
the lowest molecular weight band was of a similar sized fragment
,20-kDa as observed in endothelial cells treated with P. gingivalis
(Figure 1B-left panel). Proteolysis of rRIPK2 kd was further
inhibited with KYT-36, and completely inhibited in the presence
of both KYT-1 and KYT-36, or with TLCK. We also observed
that pretreatment of P. gingivalis with caspase inhibitors prevented
proteolysis, with zVAD-fmk activity having a greater effect than
BocD-fmk activity. The ability of these peptide inhibitors to
prevent P. gingivalis-induced proteolysis of RIPK2 in a cell-free
system is similar to our findings observed in endothelial cell
culture. These findings support the notion that P. gingivalis may
bypass cellular activation mechanisms and directly induce the
proteolysis of RIPK2 and other intracellular proteins via Kgp-
specific cleavage.
Discussion
In this study, we demonstrate that the P. gingivalis lysine-specific
cysteine protease, Kgp, induced the novel proteolysis of RIPK1,
Figure 5. General caspase inhibitors z-VAD-FMK and Boc-D-FMK alter P. gingivalis-induced modification of RIPK1 and RIPK2 in
HUVEC. HUVEC were pretreated (Pre-Tx) with medium (M), 0.25% DMSO vehicle control (C), 25 mM z-VAD-FMK (VAD), or 100 mM Boc-D-FMK (Boc)
with for 1.5 h. HUVEC were then treated with medium (M)o rP. gingivalis strain 381 (MOI 100, 381) for 2 h. Whole cell lysates were analyzed for (A)
RIPK1 or (B) RIPK2 and GAPDH. Full-length RIPK1 and RIPK2 are indicated with arrows. Prominent P. gingivalis-induced LMW bands are indicated with
asterisks. MW ladder is indicated on the left in kDa.
doi:10.1371/journal.ppat.1002723.g005
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RIPK1 and RIPK2 reduced full-length protein levels and
generated low molecular weight fragments. P. gingivalis-induced
proteolysis was dose-dependent and inhibited through heat
inactivation. In contrast, the induction of apoptosis of human
endothelial cells by classical apoptotic stimuli did not induce the
cleavage of RIPK1 or RIPK2. Furthermore, activation of
canonical signaling pathways mediated by RIPK2 did not induce
the proteolysis of RIPK2 with defined agonists to TLR2, TLR4,
NOD1 and NOD2. Through the use of chemical inhibition and
isogenic bacterial strains, we demonstrate the proteolysis of
RIPK1, RIPK2 and PARP in endothelial cells was mediated
specifically by P. gingivalis Kgp, and not by Rgp activity. In a cell-
free assay we further demonstrated that P. gingivalis induced the
direct proteolysis of recombinant RIPK2, which was inhibited in
the presence of specific protease inhibitors. Our findings indicate
that the proteolysis of RIPK1, RIPK2 and PARP induced by P.
gingivalis can occur directly and does not require activation of
innate immune signaling pathways or caspase-dependent apoptot-
ic pathways.
The endothelial cell response to P. gingivalis infection has been
described as that of an inflammatory nature with minimal
apoptosis [33,35,36,37,39,47]. In the current study we demon-
strate that P. gingivalis-induced proteolysis of key proteins that
mediate TNF-R superfamily-induced apoptosis, including RIPK1,
RIPK2 and PARP [1,64,65,66]. Previous reports demonstrated
caspase-mediated cleavage of RIPK1, RIPK3 and RIPK4 in
immortalized cell lines in response to death receptor activation
[22,23,24,25]. To our knowledge there have not been any reports
demonstrating the cleavage of RIPK2 by induction of apoptosis or
by a microbial pathogen. In contrast to the cleavage of RIPK
family members in cell lines, we did not observe the cleavage of
RIPK1 or RIPK2 in primary endothelial cells treated with similar
apoptotic conditions. Furthermore, the size of the cleavage
fragments of RIPK1 generated between Meylan and coworkers
and those by P. gingivalis differed, which may be reflective of the
cell types and mechanisms involved.
The degree of apoptosis (monitored by annexin V staining and
caspase 3 cleavage) we observed by P. gingivalis-treated endothelial
cells was minimal relative to the degree of RIPK1 and RIPK2
Figure 6. P. gingivalis modifies RIPK2 in wild type and caspase-deficient murine bone marrow-derived macrophages. A) C57BL/6 (wt)
or casp1-deficient (casp1
2/2) BMDM were untreated (M) or treated with 100 ng/ml E. coli LPS (LPS), live P. gingivalis 381 (MOI 100, Live) or heat-
killed (60uC, 60 min) P. gingivalis 381 (MOI 100 equivalency, HK) for 2 h. B) C57BL/6 (wt), casp2-deficient (casp2
2/2), casp3-deficient (casp3
2/2), or
casp7-deficient (casp7
2/2) BMDM were untreated (2) or treated with P. gingivalis 381 (MOI 100) (+) for 2 h. Whole cell lysates were analyzed for
RIPK2. Full-length RIPK2 is indicated with an arrow. A prominent P. gingivalis-induced LMW band is indicated with an asterisk. MW ladder is indicated
on the left in kDa.
doi:10.1371/journal.ppat.1002723.g006
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PLoS Pathogens | www.plospathogens.org 8 June 2012 | Volume 8 | Issue 6 | e1002723Figure 7. KYT inhibitors specifically inhibit P. gingivalis gingipain activity and do not alter host 3 caspase activity. Effect of gingipain
inhibitors on P. gingivalis A) Rgp or B) Kgp protease activity. P. gingivalis was untreated (none) or pretreated with 10 mM Rgp-specific inhibitor KYT-1,
10 mM Kgp-specific inhibitor KYT-36, 10 mM KYT-1 and 10 mM KYT-36, 1 mM TLCK, or vehicle controls (DMSO or acid water) for 10 min and monitored
for arginine-X-specific or lysine-X-specific protease activity. Effect of inhibitors on P. gingivalis is presented as percent Rgp-X activity or Kgp-X activity
relative to untreated P. gingivalis. C) HUVEC were untreated or treated with 2 mM staurosporine (STS) for 5 h. Whole cell lysates were analyzed for
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caspase inhibitor was included to demonstrate observed fluorescence is specific to caspase-3 like proteases. Statistical analysis was performed using
unpaired T-test (a=0.05), **p,0.001, NS=no significance.
doi:10.1371/journal.ppat.1002723.g007
Figure 8. Inhibition of Kgp activity alters P. gingivalis-mediated RIPK1 and RIPK2 cleavage in HAEC. P. gingivalis strain 381 was
pretreated with 10 mM KYT-1, 10 mM KYT-36, 10 mM KYT-1 and 10 mM KYT-36, 1 mM TLCK, or vehicle controls (DMSO or acid water) for 45 min. HAEC
were then immediately co-cultured with medium or with pretreated preparations of P. gingivalis 381 (MOI 100) for 2 h. Whole cell lysates were
analyzed for A) RIPK1 or B) RIPK2. Full-length RIPK1 and RIPK2 are indicated with arrows. Prominent P. gingivalis-induced LMW bands are indicated
with asterisk(s). MW ladder is indicated on the left in kDa. GAPDH was detected as a loading control.
doi:10.1371/journal.ppat.1002723.g008
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particular, at later time points (24 h) during the infection supports
the notion that P. gingivalis did not induce a caspase-mediated cell
death program in endothelial cells, as de novo synthesis of PARP
would not be expected in apoptotic cells. Although host factors
may contribute to our observations, our findings with caspase
inhibitors, caspase-deficient BMDM and cell-free assays suggest
that the proteolysis of RIPK1, RIPK2 and PARP was not a
caspase-mediated event, but was driven by the proteolytic activity
of P. gingivalis Kgp. Virulence factors by other pathogens, including
the catalytic activity of Yersinia enterocolitica outer protein P (YopP)
and murine cytomegalovirus M45-encolded viral inhibitor of RIP
activation (vIRA) have been shown to induce the caspase-mediated
cleavage of RIPK1 or disruption of the pronecrotic RIPK1-
RIPK3 complex, respectively, to promote cell death pathways
[67,68,69]. Bacterial cell extracts or purified gingipains from P.
gingivalis have been shown to induce endothelial cell apoptosis
[50,70]. In contrast, P. gingivalis Kgp-mediated cleavage of RIPK1
and RIPK2 in the context of viable whole bacteria may function to
prevent activation of cell death pathways and serve to create an
intracellular niche for bacterial persistence.
It is unclear if intracellular NLR activation contributes to host
defense against live P. gingivalis. Bacterial components of P. gingivalis
have been implicated to have a stimulatory effect of NOD1 and
Figure 9. P. gingivalis Kgp mutant is deficient in the induction of RIPK1 and RIPK2 proteolysis in HAEC. HAEC were untreated or treated
with P. gingivalis strain 381, strain ATCC 33277, or isogenic mutants of 33277: YPP1 (rgpA
2), RgpA/B (rgpA
2, rgpB
2), or with YPP2 (kgp
2) (MOI 100) for
2 h. Whole cell lysates were analyzed for A) RIPK1 or B) RIPK2. Full-length RIPK1 and RIPK2 are indicated with arrows. Prominent P. gingivalis-induced
LMW bands are indicated with asterisks. MW ladder is indicated on the left in kDa. GAPDH was detected as a loading control.
doi:10.1371/journal.ppat.1002723.g009
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NALP3 has been described in diseased human gingival tissue
[71,72,73]. In contrast, the role of membrane-bound TLR in P.
gingivalis infection and pathogenesis has been more thoroughly
evaluated [33,34,35,37,39,47,74]. We previously demonstrated
that P. gingivalis primes human endothelial cells for further TLR2
and TLR4 stimulation by inducing the up regulation of cell surface
expression of TLR from intracellular stores [38,48]. We also
reported that P. gingivalis major and minor fimbriae induce IL-8
production in endothelial cells via TLR2 and TLR4/MD-2
signaling pathways [48]. TLR2 has also been demonstrated to
mediate P. gingivalis-induced inflammatory bone loss in vivo [34,75]
and atherosclerotic lesion development in a ApoE
2/2 mouse
model [34,76].
An additional observation from these studies was the differential
response by primary human endothelial cells to defined NOD and
TLR agonists. We show that endothelial cells generated greater
IL-8 secretion in response to NOD1 agonists as compared to that
observed with TLR2, TLR4, and NOD2 agonists. Following
stimulation with invasive bacteria, NOD1 and NOD2 translocate
to the plasma membrane and recruit RIPK2 to mediate NF-kB
and MAPK activation of host defenses [9,77,78]. Recent studies
have also reported the importance of NOD1 in host defense by
endothelial cells to intracellular bacteria, including Chlamydophila
pneumoniae, Listeria monocytogenes, and Orientia tsutsugamuschi [6,7,79].
Although these reports did not evaluate the role of NOD1 on
pathogen survival in endothelial cells, NOD1, NOD2 and RIPK2
have demonstrated to contribute to pathogen clearance
[2,3,5,9,10,12,80]. Collectively, results presented here together
with our previous studies indicate that P. gingivalis can both trigger
TLR activation pathways while also interfering with the NOD1/
RIPK2 cascade via rapid proteolysis of RIPK2.
The ability of P. gingivalis to persist and contribute to chronic
disease may also result from disruptions in the intracellular
signaling pathways that regulate autophagy. Autophagy involves
the vesicular sequestration of organelles and the generation of
autophagosomes to recycle amino acids and macromolecules.
Autophagy can function as a cell survival mechanism, contribute
to innate immune host defense by clearance of intracellular
bacteria (xenophagy), and less often, contribute to cell death.
Given the recent understanding of RIPK1, RIPK2 and PARP
requirement in autophagy [4,18,81], our findings suggest that the
ability of P. gingivalis to rapidly induce the proteolysis of RIPK1,
RIPK2 and PARP in endothelial cells may provide a window of
opportunity to escape the activation of xenophagy, invade and
establish an intracellular niche. In support of this, it is well
documented that P. gingivalis survives within primary endothelial
cells [38,39,47]. Others and we have shown that P. gingivalis reside
intracellularly in autophagosomes [40,82,83,84]. Subversion of the
autophagic pathway has been observed with other intracellular
bacteria, including, Brucella abortus [85], Legionella pneumophila [86],
and Coxiella burnetii. However, the role of P. gingivalis gingipain
activity in modulating the autophagic machinery has not been
elucidated. Noteworthy, in our studies we observed the return of
full-length RIPK1, RIPK2 and PARP protein levels at later time
points (24 h) following infection. Nonetheless, it is unclear if
gingipain activity continues within the localized vacuole harboring
P. gingivalis for the acquisition of nutrients or if the gingipains
continue to target intracellular host proteins throughout the
infection to regulate the balance of cell survival and death.
Historically, P. gingivalis gingipains were demonstrated to
mediate proteolysis of extracellular and cell surface proteins and
facilitate invasion of host tissues. The ability of P. gingivalis
gingipains to induce the proteolysis of intracellular proteins in the
absence of live bacteria is noteworthy. Gingipain-mediated
cleavage of several intracellular structural (b-catenin, c-catenin,
p120, paxillin) and regulatory proteins (focal adhesion kinase,
SRC, and p130CAS) have been reported with the use of live P.
Figure 10. Cleavage of recombinant RIPK2 kinase by P. gingivalis in the absence of host cell proteins. P. gingivalis strain 381 was
pretreated with 10 mM KYT-1, 10 mM KYT-36, 10 mM KYT-1 and 10 mM KYT-36, 1 mM TLCK, 100 mM zVAD-fmk, 100 mM BocD-fmk with or vehicle
controls (HEPES (none), DMSO or acid water) for 45 min, then immediately co-cultured with 0.1 mg recombinant RIPK2 kinase for 1 h at 37uC.
Reactions were stopped by the addition of SDS-PAGE loading dye and analyzed by Western blot analysis with an antibody to the N9-terminal kinase
domain of RIPK2. Top panel: reaction with recombinant protein and P. gingivalis; bottom panel: 10% of reaction prior to incubation with P. gingivalis
(untreated recombinant protein, i.e., gel loading control).
doi:10.1371/journal.ppat.1002723.g010
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membrane vesicles (OMV) released by P. gingivalis (containing
fimbriae, gingipains, LPS, capsule and muramic acid)
[55,87,88,89]. Importantly, the proteolysis of these intracellular
proteins was dependent on P. gingivalis fimbriae. The subtle
proteolysis of RIPK2 we observed with the P. gingivalis fimA mutant
(DPG3) may be attributed to the poor invasion capacity of this
organism. Upon re-evaluation of our HK preparations of P.
gingivalis wild type strain 381, we observed that HK 60uC
preparations maintained a significant level of Kgp and Rgp
activity (data not shown). Similarly, the passage of fimbriae-
containing OMV from P. gingivalis 381 with residual catalytic
activity may have been sufficient to induce the partial proteolysis
of RIPK1 and RIPK2. Thus, the ability of P. gingivalis OMV and
gingipains to access intracellular host proteins is most likely
enhanced with invasive, whole organism.
Recently, the subcellular distribution of NOD receptors has
been further investigated. Using immunoflourescence and bio-
chemical fractionation of tagged proteins, NOD2 has been shown
to be localized to the plasma membrane, leading to recruitment of
RIPK2 [90]. Both NOD1 and NOD2 are recruited to invasion
foci of Shigella flexneri in HeLa cells [78], likely a mobilization
strategy where the active complex is able to activate part of the
NF-kB pathway via an ‘‘induced proximity’’ mechanism [91].
Considering RIPK2 recruitment occurred in a CARD-dependent
manner, it is likely that NOD1 may similarly function in
localization of RIPK2 to the plasma membrane, while RIPK1
recruitment occurs via TNF-R [92].
Several pathogens are internalized into host cells by clathrin-
dependent endocytosis [93], which also contain NOD2 stimula-
tory activity. MDP entry appears to occur via a similar endocytic
pathway, suggesting MDP and bacteria utilize the same route to
trigger NOD2 activation [94]. Staphylococcal peptidoglycan is
internalized via endocytosis and colocalizes with both NOD2 and
TLR2, providing additional support for overlap in cellular
distribution of PRR engagement of RIPK1 and RIPK2 in the
vicinity of organism or OMV [95].
Previous work has established that for P. gingivalis, the majority
of adherent bacteria actively invade endothelial cells, suggesting a
highly efficient endocytic uptake of organisms [47]. We speculate
that OMV can enter endothelial cells via similar mechanisms, such
as receptor mediated uptake at particular lipid raft domains, as
was shown in HeLa cells [55]; sites enriched in particular receptors
and signaling molecules. As an early endosome forms and pinches
off, initial localization of RIPK1 and RIPK2 on the plasma
membrane now places these kinases at the interior face of the
endocytic compartments, enabling their degradation via the newly
entered whole organism and/or OMV, both harboring gingipain
activity. It has recently been demonstrated that Vibrio cholera OMV
enter nonphagocytic host cells and their contents directly interact
with NOD1 and NOD2 [96]. A second scenario is that non-
vessicle bound gingipains cross the plasma membrane indepen-
dently, as occurs with RgpA in HeLa cells by a yet to be
determined mechanism [97], and directly interact with pools of
strictly cytosolic PRR. Three dimensional modeling revealed high
similarity between S2 and S3 binding pockets of RgpB and Kgp;
however, differences in the S1 pocket architecture ensure distinct
substrate specificity, suggesting potentially critical interactions
between RIPK1 or RIPK2 and Kgp, likely representing hydro-
phobic amino groups at the P2 position [98].
Increasing evidence suggests that the kinase domain of RIPK2
maintains protein stability. The reduction of RIPK2 protein
levels has been reported in studies that disrupted the catalytic
domain of the RIPK2 kinase domain. Inactivation of the ATP
binding site of RIPK2 through genetic disruption of key amino
acid residues (K38, K47, D164) or by chemical inhibition
decreased full-length RIPK2 levels, decreased autophosphory-
lation and prevented RIPK2-mediated cellular activation or
apoptosis [1,13]. Windheim and coworkers note that the
chemical inhibition of RIPK2 activity with SB 203580 decreased
RIPK2 levels within 30–60 min, and was not inhibited by
MG132 proteasome inhibition or caspase 1 inhibition in
preliminary studies. It is possible that the mechanism(s) involved
in reduction of RIPK2 in response to disruption of kinase activity
or by P. gingivalis are not equivalent. However, we may envision a
joint scenario where Kgp activity initiates the P. gingivalis-induced
proteolysis of RIPK2 by cleaving a key lysine in the catalytic
region of the kinase domain of RIPK2 (of which there are 12),
followed by a host-mediated mechanism(s) to remove the
unstable protein. Given the regulation of RIPK1 and RIPK2
by ubiquitination and deubiquitination to modulate cell fate
[8,19,26,99,100], it would be of value to identify the amino acid
site(s) of Kgp-induced cleavage of RIPK1 and RIPK2 and
determine if they are the lysines involved in kinase activity or
targets of ubiquitination. It may not be surprising that P. gingivalis
evolved with a cysteine protease that targets lysine residues, as
these unique amino acids are subject to post-translational
modifications, including phosphorylation, ubiquitination and
acetylation, to alter protein function. This may provide a
mechanism for P. gingivalis to dysregulate proteins that are
subject to post-translational modification and play a role in host
defense.
The interactions between bacteria with host defense mecha-
nisms are dynamic cellular processes involving pathogen-mediat-
ed factors and host signaling cascades, microenvironments and
appropriate immune responses. We and others have demonstrat-
ed the role of membrane-bound TLR in the recognition and host
defense against P. gingivalis. However, the roles of intracellular
PRR in P. gingivalis infection and persistence are poorly
understood. Our results demonstrate that P. gingivalis Kgp activity
induces the proteolysis of key signaling proteins involved in TNF-
mediated cell death and NOD-mediated host defense pathways.
Further studies will be required to determine the functional
consequence of these observations, in a manner that can
distinguish between RIPK1 and RIPK2-mediated processes. In
addition, studies will examine the internalization of OMV and
the extent of gingipain colocalization with PRR, RIPK1, and
RIPK2. We propose that the disruption of intracellular signaling
facilitates the persistence of P. gingivalis in endothelial cells by
evading host defense mechanisms and altering cell death
pathways (Figure 11).
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health (The
Guide). The protocol was approved by Boston University’s
Institutional Animal Care and Use Committee (IACUC) Protocol
Number AN14348. Boston University is committed to observing
Federal policies and regulations and Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC)
International standards and guidelines for humane care and use
of animals. Federal guidelines, the Animal Welfare Act (AWA) and
The Guide were followed when carrying out these experiments.
Procedures involved euthanasia and harvesting of bone marrow
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distress.
Cell culture
Human aortic endothelial cells (HAEC) (Lonza Walkersville,
Inc.) or pooled human umbilical vein endothelial cells
(HUVEC) (Lonza Walkersville, Inc.) were maintained with
Endothelial Growth Medium 2 (EGM-2) (Lonza Walkersville,
Inc.) in a 37uC incubator with 5% CO2.E x p e r i m e n t sw e r e
performed with cells (passage 3–8) seeded in 6-well plates at a
density of 2–3610
5 cells/well in EGM-2 without supplementa-
tion of antibiotics.
Mice
Wild type C57BL/6, casp2
2/2, casp3
2/2, and casp7
2/2, mice
were obtained from The Jackson Laboratories and casp1
2/2 mice
were generously provided by Dr. Robin Ingalls (Boston University
School of Medicine). Mice were sacrificed to obtain primary bone
marrow derived cells that were differentiated into macrophages
with 1X RPMI (cellgro) supplemented with 20% L929-condi-
tioned medium, 10% FBS, penicillin and streptomycin for 7 d.
Experiments were performed in 6-well plates at a BMDM cell
density of 1.5610
6 cells per well in 1X RPMI supplemented with
10% FBS.
Bacterial strains and growth media
Strains of Porphyromonas gingivalis used in these studies are
included in Table S1. Strains were maintained at 37uCo n5 %
anaerobic blood agar plates in a GasPak EZ gas generating
container system (Becton, Dickinson and Company (BD)). Wild
type P. gingivalis 381 was used in most of our studies. To evaluate
the role of gingipains, isogenic mutant strains of P. gingivalis ATCC
33277 were used, including YPP1 (rgpA
2), YPP2 (kgp
2) [57] and
RgpA/B (rgpA
2 and rgpB
2 mutant) [101]. Laboratory-prepared
blood agar plates were used in experiments comparing different
strains; otherwise, wild type strain 381 was grown on commercial
anaerobic blood agar (ABA) plates (BD). Strains YPP1, YPP2 and
RgpA/B were grown on plates supplemented with 5 mg/ml
erythromycin (Sigma). To evaluate the role of the major fimbriae,
we used DPG3 [102], a major fimbriae (fimA)-deficient isogenic
mutant strain of P. gingivalis 381 that has been described as
noninvasive/invasion-deficient of endothelial cells in vitro [35,47].
For stimulation assays, organisms were transferred from plates to
liquid cultures of bovine heart infusion (BD) broth pH 7.4
Figure 11. Model of P. gingivalis innate immune activation/invasion in endothelial cells. Outcome of innate immune responses is
representative as a balance of functional, intact pathways (TLR-left panel) and dysregulated pathways (NLR-right panel). P. gingivalis represents a
human pathogen that utilizes fimbriae for attachment and invasion of endothelial cells. Fimbriae are not only expressed on whole bacteria (A), but
within outer membrane vesicles (OMV) that are released from the cell (B), as occurs with all Gram-negative bacteria identified to date. Fimbriae bind
to TLR2 and MD2 to activate TLR2 and TLR4, resulting in the induction of NF-kB, leading to inflammation, and de novo protein synthesis (C) of cell
adhesion molecules (CAM) and TLR (TLR) expressed at the cell surface (D). Many studies have demonstrated invasion of endothelial cells by P.
gingivalis (E). However, recent studies have shown that OMV (containing fimbriae and active gingipain activity) gain entry into host cells rapidly in a
gingipain-dependent manner (E), independent of whole organism. Upon entry, intracellular gingipain activity degrades RIPK1 and RIPK2 (abrogated
by protease inhibitors) (F), resulting in a variety of possible consequences as a function of selective targeting of intracellular NOD1 or NOD2 (NOD1/2)
signaling pathways and/or disruption of RIPK1 or RIPK2-mediated cell signaling. Alteration of immune signaling responses may result in decreased
host cell death, decreased inflammatory mediator expression, and subsequent enhancement of intracellular bacterial cell survival, all of which
contributes to an intracellular niche for P. gingivalis (G).
doi:10.1371/journal.ppat.1002723.g011
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(Sigma), 1 mg/ml menadione (Sigma) and antibiotics as described
above when necessary and incubated at 37uC in an anaerobic
chamber with 85% N2,5 %H 2 and 10% CO2. Culture purity was
checked by Gram staining.
Preparation of P. gingivalis for co-culture assays
Overnight bacteria cultures were washed three times with
phosphate buffered saline (PBS) (cellgro) and resuspended in cell
culture medium to achieve a desired working concentration of
1610
9 cfu/ml bacteria as previously described [38]. Heat-killed
preparations (HK) of P. gingivalis were prepared by incubating
aliquots of the washed suspension at 60uC for 60 min as previously
described [39] or at 80uC for 20 min. Organisms were plated on
ABA plates and incubated in an anaerobic chamber for at least 5 d
to confirm the concentration of live organism or viability of HK
organism. Inhibition of P. gingivalis gingipain activity was
performed with the previously described [54] arginine-specific
gingipain inhibitor carbobenzoxy-Lys-Arg-CO-Lys-N-(CH3)2
(KYT-1) (Pepta Nova/Peptides International), the lysine-specific
gingipain inhibitor carbobenzoxy-Glu(NHN(CH3)Ph)-Lys-CO-
NHCH2Ph (KYT-36) (Pepta Nova/Peptides International) and
the general gingipain inhibitor Na-p-tosyl-L-lysine chloromethyl
ketone hydrochloride (TLCK) (Acros Organics). Washed bacterial
suspensions were pre-incubated in 10 mM KYT-1, 10 mM KYT-
36, 10 mM KYT-1 and 10 mM KYT36, or 1 mM TLCK for
45 min at 37uC prior to co-culturing with HAEC.
Arg-X-specific and Lys-X-specific whole cell protease
assays
The arginine-X-specific and lysine-X-specific protease activity
of P. gingivalis was determined using the enzymatic substrate
hydrolysis of Na-benzoyl-DL-arginine 4 p-nitroanilide (BAPNA)
(Sigma) or N-Tosylglycyl-L-prolyl-L-lysine 4-nitroanilide (Sigma),
respectively. P. gingivalis preparations were preincubated in
200 mM Tris/HCl buffer, pH 7.6, containing 100 mM NaCl,
5 mM CaCl2, and 10 mM cysteine, for 10 min at RT and assayed
for amidase activity with 0.5 mM substrate. Formation of p-
nitroanilide was monitored spectrophotometrically at 405 nm for
30 min using a Biotek Synergy HT plate reader. Each analysis was
performed in triplicate.
Caspase-3 protease activity assay
To determine if specific gingipain inhibitors affected host
caspase activity, caspase-3 activity was measured using EnzChek
caspase assay kit (Molecular Probes). HUVEC were seeded at
5610
5 cells/well in 6-well plates. Cells were untreated or treated
with 2 mM staurosporine for 5 h in order to induce caspase-3
activity. Whole cell lysates were collected and placed in reaction
buffer (10 mM PIPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS) with
dimethyl sulfoxide (DMSO) (Sigma), KYT-36 (3 mM), or Ac-
DEVD-CHO caspase inhibitor (20 mM) and incubated for
10 min. Lysates were placed into 96-well plates containing Z-
DEVD-AMC substrate (100 mM). Fluorescence (excitation/emis-
sion ,342/441 nm) was measured after 60 min. The fold change
in fluorescence was calculated relative to untreated. Data
represents the average of three replicate experiments.
Co-culture/Stimulation assays
Cell stimulation assays were performed in a 37uC humidified
chamber with 5% CO2 and were performed at least three times.
Cells were treated with medium (new cell culture medium), live
organisms, inactivated organisms or with commercially available
synthetic or purified cell agonists at a concentration and
incubation period indicated in each figure legend. Agonists used
in this work include synthetic bacterial tripalmitoylated lipopeptide
Pam3CSK4 (TLR1/TLR2 agonist), synthetic diacylated lipopro-
tein of Mycoplasma fermentans FSL-1 (TLR2/TLR6 agonist),
ultrapure P. gingivalis strain ATCC 33277 LPS (TLR2/TLR4
agonist), ultrapure E. coli strain 0111:B4 LPS (TLR4 agonist), c-D-
glutamyl-meso-diaminopimelic acid (iE-DAP, NOD1 agonist), N-
acetylmuramyl-L-alanyl-D-isoglutamine (MDP, NOD2 agonist),
acylated iE-DAP (C12-iE-DAP, NOD1 agonist) acylated MDP
(L18-MDP, NOD2 agonist) control peptides for iE-DAP or MDP
including iE-Lys (c-D-glutamyl-lysine, a dipeptide present in the
peptidoglycan of Gram-positive bacteria) or with an inactive D-D
isomer of MDP [103] (all from InvivoGen), and recombinant
human TNF (TNF-R1 agonist) (BD Pharmingen).
Inhibition of endothelial cell protein synthesis or caspase
activity
For some experiments, endothelial cells were pretreated with
cellular inhibitors including the general protein synthesis inhibitor
cycloheximide (Sigma), caspase inhibitors zVAD-FMK (R&D
Systems) or Boc-D-FMK (BioVison), or with vehicle control,
DMSO.
Apoptosis assays and flow cytometry
Induction of apoptosis of endothelial cells was performed with
treatment with staurosporine, or co-treatment with cycloheximide
and recombinant TNF at the concentration and the time points
indicated. Cells were either analyzed by Western blot to monitor
caspase 3 cleavage or by flow cytometry to monitor Annexin V
and propidium iodide (PI) staining. For flow cytometry, adherent
cells were removed with a trypsin-EDTA solution and pooled with
the floating fraction. Cells were stained with Annexin V eFluor
450 Apoptosis Detection Kit (eBioscience) using the manufactur-
er’s protocol. Just before acquisition, PI was added to distinguish
dead versus apoptotic cells. At least 10,000 events were acquired
on a BD LSR II flow cytometer. Data were analyzed using FlowJo
(Tree Star, Inc.).
Sample processing and Western blot analysis
Stimulation assays were ceased by immediately placing cell
culture plates on ice washing cells three times with ice-cold PBS
and addition of RIPA lysis Buffer [20 mM Tris HCl, pH 7.5,
150 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM EGTA, 1%
sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM b-
glycerophosphate] supplemented with complete protease inhibitor
cocktail (Roche) and PhosSTOP phosphatase inhibitor cocktail
(Roche). Cells were scraped from the plate, cell lysates were
harvested and placed on ice for 30 min with occasional vortexing.
Samples were clarified of cellular debris by micro centrifugation at
13,200 rpm for 15 min at 4uC. The protein concentration of the
clarified lysates was determined by a bicinchoninic acid protein
assay (Sigma). Samples were prepared for Western blot by
combining clarified whole cell lysates with Laemmli sample buffer
(Bio-Rad Laboratories) supplemented with dithiothreitol (Sigma)
for a final concentration of 100 mM, and heated for 10 min at
100uC to denature proteins. Samples (20–40 mg) were separated
on SDS-PAGE gels, transferred to polyvinyldifluoride membranes,
blocked in 5% milk and immunoblotted for target proteins.
Primary antibodies used in this study include a a mouse
monoclonal antibody to caspase 3 (clone 3G2), as rabbit polyclonal
antibody to cleaved caspase 3 (clone Asp175), a rabbit polyclonal
antibody to NOD1 (Cell Signaling Technology), a mouse
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PARP (Cell Signaling Technology), a mouse antibody to RIPK1
(clone G322-2) (BD Biosciences), a rabbit polyclonal antibody to
the N9-terminus of RIPK2 (Axxora Platform), a mouse monoclo-
nal antibody to the C9-terminus of RIPK2 (Abcam), and a rabbit
monoclonal antibody to GAPDH (clone 14C10; Cell Signaling
Technology) as a sample loading control. Secondary antibodies
include HRP-linked anti-mouse IgG, (GE Amersham) and HRP-
linked anti-rabbit IgG (Cell Signaling Technology). Membranes
were exposed to enhanced chemiluminescence (GE Amersham)
and signal intensity was documented by exposing membranes to
film. All Western blots performed to monitor the levels of RIPK2
in this study were analyzed with both N9-terminal- and C9-
terminal-directed antibodies. However, all blots for RIPK2
detection presented in this report are with the N9-terminal
antibody, except for Figure 1B that includes both N9-terminal
and C9-terminal antibody immunoblots.
Densitometry
Quantification of Western Blot protein signal intensity levels
was acquired by either a charged coupled device camera, LAS
4000 luminescent image analyzer (Fujifilm) and assessed by
Multigauge 3.0 software (Fujifilm) or by a Kodak DC290 zoom
digital camera and assessed by Kodak 1D v.3.6.0 software.
Membrane background values were subtracted from protein
intensity values. Data is presented as the mean and standard
error of the mean (SEM) ratio of the target protein (NOD1,
NOD2, RIPK1, or RIPK2) to the loading control (GAPDH).
Cell-free assays
Washed suspensions of overnight cultures of P. gingivalis 381
were prepared similarly as above, except suspensions were
resuspended in 30 mM HEPES buffer (Lonza Walkersville, Inc.).
P. gingivalis strain 381 was pretreated with 10 mM KYT-1, 10 mM
KYT-36, 10 mM KYT-1 and 10 mM KYT-36, 1 mM TLCK,
100 mM zVAD-fmk, 100 mM BocD-fmk with or vehicle controls
(HEPES, DMSO or acid water) for 45 min, then immediately co-
cultured with 0.1 mg recombinant RIPK2 kinase (Invitrogen) for
1 h in a humidified chamber at 37uC with 5% CO2. Ten percent
of initial reactions were harvested for gel loading controls.
Reactions were stopped by the addition of SDS-PAGE loading
dye and analyzed by Western blot analysis with an antibody to the
N9-terminal kinase domain of RIPK2.
ELISA
Cell culture supernatants were collected from stimulation assays
(performed in triplicate), clarified of bacteria and cellular debris
and assayed in triplicate by ELISA. Supernatants from HAEC
were assayed with ELISA kit specific for detection of human IL-8
according to the manufacturer’s instructions with limit of detection
of 3.1 pg/ml (BD Biosciences).
Statistics
Statistical analysis of ELISA data, densitometry and caspase 3
assay activity data was performed with GraphPad Prism 5 software
for two-tailed unpaired T test (a=0.05).
Supporting Information
Figure S1 Schematic of antibody recognition sites of
RIPK1 and RIPK2 antibodies used in this study. Antibodies
used include A) a carboxyl (C9)-terminal-targeted antibody that
detects the intermediate region and death domain of RIPK1, and
B) an amino (N9)-terminal polyclonal antibody that detects the
kinase domain of RIPK2 (AA 11–30) and a C9-terminal
monoclonal antibody that detects the CARD of RIPK2 (AA
431–541).
(EPS)
Figure S2 Proteolysis of RIPK1 and RIPK2 in HUVEC
by P. gingivalis DPG3 is attenuated. HUVEC were treated
with medium (M,-), P. gingivalis 381 at a MOI of 10 (10) or 100
(100), or with the fimA mutant, DPG3, at a MOI of 10 or 100 for
6 h. Whole cell lysates were analyzed for the detection of RIPK1
(left panel) or RIPK2 (right panel). Full-length RIPK2 is indicated
with an arrow. Prominent P. gingivalis-induced LMW bands are
indicated with asterisks. MW ladder is indicated on the left in kDa.
GAPDH was detected as a loading control. Densitometric analysis
is presented below respective blots as the percent mean ratio of
RIPK1 (or RIPK2) to GAPDH protein levels (arbitrary densito-
metric units (A.D.U.).
(EPS)
Figure S3 The P. gingivalis-induced LMW bands in
HUVEC are not new protein products. HUVEC were
untreated (2) or pretreated (+) with 25 mg/ml cyclohexamide
(CHX) for 30 min, followed by treatment with medium (M),
50 ng/ml TNF (TNF)o rP. gingivalis strain 381 (381, MOI 100)
for 2 h. Whole cell lysates were analyzed by Western blot for the
detection of RIPK1 (left panel) RIPK2 (right panel). Prominent P.
gingivalis-induced LMW bands are indicated with asterisks. MW
ladder is indicated on the left in kDa. GAPDH was detected as a
loading control. Cleaved and full-length caspase 3, and PARP
were monitored to confirm the effect of CHX.
(EPS)
Figure S4 TLR and NLR agonist-induction of HAEC IL-8
levels. HAEC were treated with medium, 10 mg/ml Pam3CSK4,
10 mg/ml FSL-1, 10 mg/ml P. gingivalis 381 LPS, 1.0 mg/ml E. coli
0111:B4 LPS, 100 mg/ml iE-DAP, 1000 ng/ml C12-iE-DAP,
100 mg/ml MDP, 1000 ng/ml L18-MDP or 100 ng/ml recombi-
nant human TNFa for A)6h ,B) 12 h and C) 24 h and evaluated
for cell culture supernatant IL-8 levels. Statistical significance
between groups was performed by un-paired, two-tailed T-test
(a=0.05), and indicated with asterisk, with *=p,0.05,
**=p,0.01 and ***=p,0.001, or ns=non significant.
(EPS)
Figure S5 Induction of apoptotic markers in HUVEC in
response to classical apoptotic stimuli or P. gingivalis.
HUVEC were treated with medium, P. gingivalis 381 (MOI 10 or
100), 2 mM staurosporine (STS) 25 mg/ml cycloheximide (CHX),
10 ng/ml TNFa, or co-treated with 25 mg/ml CHX and 10 ng/ml
TNFa for 6 h. A) Flow cytometric analysis of annexin V and
propidium iodide (PI) staining of HUVEC treated as indicated.
Apoptotic cells which retain membrane integrity are Annexin V
positive/PI negative, whereas necrotic cells with compromised
membrane integrity are Annexin V positive/PI positive. B) Whole
cell lysates were analyzed for the detection of full-length (fl.) and
cleaved (c.) caspase 3 (with an antibody that detects a 17- and 19-
KDa fragment) and full-length (fl.) and cleaved (c.) PARP. MW
ladder is indicated on the left in kDa. GAPDH was detected as a
loading control.
(EPS)
Figure S6 Boc-D-FMK has minimal effect in P. gingiva-
lis-induced proteolysis of RIPK1, RIPK2 and PARP.
HUVEC were pre-treated (Pre-Tx) with medium (M), 0.25%
DMSO vehicle control (C), or 100 mM Boc-D-FMK (Boc) for 1 h.
HUVEC were then treated with medium (M), P. gingivalis 381
(MOI 100) or 2 mM staurosporine (STS) for 1.5 h. Whole cell
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PARP (lower panel) and GAPDH (bottom panel). Full-length
RIPK1 and RIPK2 are indicated with arrows. Prominent P.
gingivalis-induced LMW bands are indicated with asterisks. MW
ladder is indicated on the left in kDa.
(EPS)
Figure S7 Lysine-specific gingipain (Kgp) activity me-
diates P. gingivalis-induced modification of PARP in
HAEC. A) Kinetics of PARP levels in HAEC in response to P.
gingivalis 381. HAEC were treated with medium (M) or with P.
gingivalis strain 381 (MO1 100) for 0.25, 0.5, 1, 2, 6, 12, 24 or 48 h.
Whole cell lysates were analyzed for the detection of PARP (116-
kDa). Full-length PARP is indicated with an arrow. MW ladder is
indicated on the left in kDa. GAPDH was detected as a loading
control. B) P. gingivalis strain 381 was pretreated with 10 mM
KYT-1, 10 mM KYT-36, 10 mM KYT-1 and 10 mM KYT-36,
1 mM TLCK, or vehicle controls (DMSO or acid water) for
45 min. HAEC were then immediately co-cultured with medium,
or with the pretreated preparations of P. gingivalis 381 (MOI 100)
for 2 h. Whole cell lysates were analyzed for PARP and GAPDH.
C) HAEC were treated with medium or P. gingivalis strain 381,
strain ATCC 33277, or isogenic mutants of 33277: YPP1 (rgpA
2),
or with YPP2 (kgp
2) at an MOI of 100 for 2 h. Whole cell lysates
were analyzed for PARP and GAPDH.
(EPS)
Table S1 Bacterial strains used in this study.
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